Jesus Paez-Mayorga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jesus Paez-Mayorga has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Grattoni
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Surgery, Houston Methodist Hospital, Houston, TX 77030, USA; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX 77030, USA
6 shared publications Corrine Ying Xuan Chua
Department of Nanomedicine, Houston Methodist Research Institute, Houston, USA
5 shared publicationsJoan E. Nichols
Center for Tissue Engineering, Houston Methodist Research Institute, Houston, USA
4 shared publications- Simone Capuani
Department of Nanomedicine Houston Methodist Research Institute Houston TX 77030 USA
4 shared publications Jean A. Niles
Center for Tissue Engineering, Houston Methodist Research Institute, Houston, USA
3 shared publicationsNathanael Hernandez
Department of Nanomedicine, Houston Methodist Research Institute, Houston, USA
3 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (28) , e20914
Profiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation
Systemic immunosuppression remains essential for preventing allogeneic transplant rejection, but its chronic use causes substantial toxicity. Conceptually, local, site‐specific immunomodulation offers a promising alternative, yet comparative mechanistic insight into how immunosuppressants behave when delivered directly to the graft is lacking. Here, we leveraged the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, a subcutaneous, vascularized cell‐encapsulation platform, as a spatially defined and reproducible model to study local immunomodulation in allogeneic islet transplantation. We systematically profiled the safety, local and systemic immunomodulatory effects, pharmacokinetics, and longitudinal biodistribution of five clinically relevant agents delivered locally at the graft site: CTLA4‐Ig, anti‐lymphocyte serum, anti‐CD40L, anti‐CD2, and anti‐IL6. Sustained in situ exposure did not impair islet viability or function, and immunosuppressants were confined within the graft, with up to 100‐fold lower systemic concentrations. Individual agents produced distinct immune signatures, spanning lymphocyte depletion and shifts in T‐cell activation that can guide rational, mechanism‐informed combinations for allogeneic cell transplantation. These findings provide a comparative framework for evaluating localized immunosuppression with the potential to transform immunoprotection in cell therapy.
- 6 March 2026
- Published by Wiley in Advanced Science
- Vol. 13 (28) , e20914
Open AccessProfiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation
Systemic immunosuppression remains essential for preventing allogeneic transplant rejection, but its chronic use causes substantial toxicity. Conceptually, local, site‐specific immunomodulation offers a promising alternative, yet comparative mechanistic insight into how immunosuppressants behave when delivered directly to the graft is lacking. Here, we leveraged the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, a subcutaneous, vascularized cell‐encapsulation platform, as a spatially defined and reproducible model to study local immunomodulation in allogeneic islet transplantation. We systematically profiled the safety, local and systemic immunomodulatory effects, pharmacokinetics, and longitudinal biodistribution of five clinically relevant agents delivered locally at the graft site: CTLA4‐Ig, anti‐lymphocyte serum, anti‐CD40L, anti‐CD2, and anti‐IL6. Sustained in situ exposure did not impair islet viability or function, and immunosuppressants were confined within the graft, with up to 100‐fold lower systemic concentrations. Individual agents produced distinct immune signatures, spanning lymphocyte depletion and shifts in T‐cell activation that can guide rational, mechanism‐informed combinations for allogeneic cell transplantation. These findings provide a comparative framework for evaluating localized immunosuppression with the potential to transform immunoprotection in cell therapy.
- Open Access
- 25 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Insulin resistance and metabolic health predict cardiorespiratory fitness: cohort study
Aims/aims: Decreased cardiorespiratory fitness (CRF) is an all-cause mortality predictor. Oxygen consumption at peak exercise (VO2max) during a cardiopulmonary exercise test (CPET) is the gold standard for its evaluation. Since cardiometabolic risk factors reduce CRF, we aimed to assess the cardiopulmonary and metabolic responses during CPET and evaluate their determinants. Methods and results: Subjects underwent incremental treadmill CPET and bioelectrical impedance analysis. Insulin sensitivity was estimated using the HOMA, QUICKI, and METS-IR indices. Multivariate regressions were used to evaluate determinants of VO2max. Nonlinearity was confirmed with an F-test between linear and polynomial models. Five hundred and three subjects were evaluated, 474 met maximum effort criteria, (64% females). Median age was 4(26–52); 41% had normal weight, 33% overweight, 26% obesity. Prevalence of insulin resistance ranged from 22% to 46%, depending on the equation used. VO2max was 29.8(24–36) and 36.6 (30.6–43.3) mL/kg/min for females and males. Body composition analysis revealed that a higher BMI exhibited strong biological collinearity with metrics associated with adiposity excess and was inversely associated with CRF. After adjusting for age, sex, BMI, and fat mass, insulin resistance evaluated by QUICKI explained up to 43% of VO2max variability and was inversely associated with CRF. Conclusion: In a cohort of individuals without established CVD, the main determinants of CRF were modifiable risk factors associated with excess adiposity and insulin resistance. The potential mechanisms underlying the reduction in CRF include decreased relative muscle mass and insulin resistance, which reduce muscle glucose uptake and O2 consumption during maximum effort, where anaerobic glycolysis plays a central role.
- 25 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Open AccessInsulin resistance and metabolic health predict cardiorespiratory fitness: cohort study
Aims/aims: Decreased cardiorespiratory fitness (CRF) is an all-cause mortality predictor. Oxygen consumption at peak exercise (VO2max) during a cardiopulmonary exercise test (CPET) is the gold standard for its evaluation. Since cardiometabolic risk factors reduce CRF, we aimed to assess the cardiopulmonary and metabolic responses during CPET and evaluate their determinants. Methods and results: Subjects underwent incremental treadmill CPET and bioelectrical impedance analysis. Insulin sensitivity was estimated using the HOMA, QUICKI, and METS-IR indices. Multivariate regressions were used to evaluate determinants of VO2max. Nonlinearity was confirmed with an F-test between linear and polynomial models. Five hundred and three subjects were evaluated, 474 met maximum effort criteria, (64% females). Median age was 4(26–52); 41% had normal weight, 33% overweight, 26% obesity. Prevalence of insulin resistance ranged from 22% to 46%, depending on the equation used. VO2max was 29.8(24–36) and 36.6 (30.6–43.3) mL/kg/min for females and males. Body composition analysis revealed that a higher BMI exhibited strong biological collinearity with metrics associated with adiposity excess and was inversely associated with CRF. After adjusting for age, sex, BMI, and fat mass, insulin resistance evaluated by QUICKI explained up to 43% of VO2max variability and was inversely associated with CRF. Conclusion: In a cohort of individuals without established CVD, the main determinants of CRF were modifiable risk factors associated with excess adiposity and insulin resistance. The potential mechanisms underlying the reduction in CRF include decreased relative muscle mass and insulin resistance, which reduce muscle glucose uptake and O2 consumption during maximum effort, where anaerobic glycolysis plays a central role.
- Open Access
- 14 December 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (12) , e70164
Impaired Cardiorespiratory Fitness in Type 1 Diabetes Is Associated With Metabolic Inflexibility and Specific Factors According to Sex
Background: People with long‐term type 1 diabetes have reduced cardiorespiratory fitness (CRF). We aimed to assess the influence of body composition, energy substrate use, and blood glucose control on cardiopulmonary exercise test performance in subjects with uncomplicated, long‐term type 1 diabetes. Methods: Observational, cross‐sectional study. Subjects with and without type 1 diabetes, paired by sex and age, underwent treadmill cardiopulmonary exercise test, bioelectrical impedance analysis, indirect calorimetry at rest and during exercise. We used the t ‐pair test; multivariate linear regression models and mediation analysis were used to evaluate determinants of CRF. Results: 54 cases and 54 controls (52% female) were evaluated. The age was 39 (28–46) years, duration of disease 21 ± 10 years. HbA1c 7.9 (7.3–8.7). The baseline physical activity, resting energy expenditure, respiratory quotient and body composition were similar between groups. VO2max was 32 ± 9.2 versus 39 ± 7.9 mL/kg/min ( p < 0.01) for cases and controls. Maximum carbohydrate oxidation was 809 (614–1174) versus 1082 (863–1454) ( p < 0.01), respectively. In women 73% and 25% of the effect of diabetes status on VO2max were mediated by carbohydrate oxidation and heart rate reserve, respectively. In men 78% and 57% of the effect of diabetes status on VO2max were mediated by carbohydrate oxidation and phase angle, respectively. Conclusions: Type 1 diabetes group had an altered CRF with lower carbohydrate oxidation. This suggests altered metabolic flexibility due to low substrate availability that could explain the earlier fatigue during intense exercise. There were different determinants of VO2max in persons with diabetes according to sex.
- 14 December 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (12) , e70164
Open AccessImpaired Cardiorespiratory Fitness in Type 1 Diabetes Is Associated With Metabolic Inflexibility and Specific Factors According to Sex
Background: People with long‐term type 1 diabetes have reduced cardiorespiratory fitness (CRF). We aimed to assess the influence of body composition, energy substrate use, and blood glucose control on cardiopulmonary exercise test performance in subjects with uncomplicated, long‐term type 1 diabetes. Methods: Observational, cross‐sectional study. Subjects with and without type 1 diabetes, paired by sex and age, underwent treadmill cardiopulmonary exercise test, bioelectrical impedance analysis, indirect calorimetry at rest and during exercise. We used the t ‐pair test; multivariate linear regression models and mediation analysis were used to evaluate determinants of CRF. Results: 54 cases and 54 controls (52% female) were evaluated. The age was 39 (28–46) years, duration of disease 21 ± 10 years. HbA1c 7.9 (7.3–8.7). The baseline physical activity, resting energy expenditure, respiratory quotient and body composition were similar between groups. VO2max was 32 ± 9.2 versus 39 ± 7.9 mL/kg/min ( p < 0.01) for cases and controls. Maximum carbohydrate oxidation was 809 (614–1174) versus 1082 (863–1454) ( p < 0.01), respectively. In women 73% and 25% of the effect of diabetes status on VO2max were mediated by carbohydrate oxidation and heart rate reserve, respectively. In men 78% and 57% of the effect of diabetes status on VO2max were mediated by carbohydrate oxidation and phase angle, respectively. Conclusions: Type 1 diabetes group had an altered CRF with lower carbohydrate oxidation. This suggests altered metabolic flexibility due to low substrate availability that could explain the earlier fatigue during intense exercise. There were different determinants of VO2max in persons with diabetes according to sex.
- Open Access
- 26 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-20
Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats
Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent, male rat model. We demonstrated that allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing toxicity or systemic immunosuppression. Moreover, for translatability efforts, we showed NICHE biocompatibility and feasibility of deployment as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model. In sum, the NICHE holds promise as a viable approach for safe and effective islet transplantation and long-term T1D management.
- 26 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-20
Open AccessImplantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats
Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent, male rat model. We demonstrated that allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing toxicity or systemic immunosuppression. Moreover, for translatability efforts, we showed NICHE biocompatibility and feasibility of deployment as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model. In sum, the NICHE holds promise as a viable approach for safe and effective islet transplantation and long-term T1D management.
- Open Access
- 11 August 2022
- Published by Elsevier in Materials Today Bio
- Vol. 16, 100390
Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment
- 11 August 2022
- Published by Elsevier in Materials Today Bio
- Vol. 16, 100390
Open AccessLocalization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment
- Open Access
- 1 October 2020
- Published by Elsevier in Biomaterials
- Vol. 257, 120232
Neovascularized implantable cell homing encapsulation platform with tunable local immunosuppressant delivery for allogeneic cell transplantation
- 1 October 2020
- Published by Elsevier in Biomaterials
- Vol. 257, 120232
Open AccessNeovascularized implantable cell homing encapsulation platform with tunable local immunosuppressant delivery for allogeneic cell transplantation
- 31 August 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 9 (19) , e2000670
Enhanced In Vivo Vascularization of 3D‐Printed Cell Encapsulation Device Using Platelet‐Rich Plasma and Mesenchymal Stem Cells
The current standard for cell encapsulation platforms is enveloping cells in semipermeable membranes that physically isolate transplanted cells from the host while allowing for oxygen and nutrient diffusion. However, long‐term viability and function of encapsulated cells are compromised by insufficient oxygen and nutrient supply to the graft. To address this need, a strategy to achieve enhanced vascularization of a 3D‐printed, polymeric cell encapsulation platform using platelet‐rich plasma (PRP) and mesenchymal stem cells (MSCs) is investigated. The study is conducted in rats and, for clinical translation relevance, in nonhuman primates (NHP). Devices filled with PRP, MSCs, or vehicle hydrogel are subcutaneously implanted in rats and NHP and the amount and maturity of penetrating blood vessels assessed via histopathological analysis. In rats, MSCs drive the strongest angiogenic response at early time points, with the highest vessel density and endothelial nitric oxide synthase (eNOS) expression. In NHP, PRP and MSCs result in similar vessel densities but incorporation of PRP ensues higher levels of eNOS expression. Overall, enrichment with PRP and MSCs yields extensive, mature vascularization of subcutaneous cell encapsulation devices. It is postulated that the individual properties of PRP and MSCs can be leveraged in a synergistic approach for maximal vascularization of cell encapsulation platforms.
- 31 August 2020
- Published by Wiley in Advanced Healthcare Materials
- Vol. 9 (19) , e2000670
Enhanced In Vivo Vascularization of 3D‐Printed Cell Encapsulation Device Using Platelet‐Rich Plasma and Mesenchymal Stem Cells
The current standard for cell encapsulation platforms is enveloping cells in semipermeable membranes that physically isolate transplanted cells from the host while allowing for oxygen and nutrient diffusion. However, long‐term viability and function of encapsulated cells are compromised by insufficient oxygen and nutrient supply to the graft. To address this need, a strategy to achieve enhanced vascularization of a 3D‐printed, polymeric cell encapsulation platform using platelet‐rich plasma (PRP) and mesenchymal stem cells (MSCs) is investigated. The study is conducted in rats and, for clinical translation relevance, in nonhuman primates (NHP). Devices filled with PRP, MSCs, or vehicle hydrogel are subcutaneously implanted in rats and NHP and the amount and maturity of penetrating blood vessels assessed via histopathological analysis. In rats, MSCs drive the strongest angiogenic response at early time points, with the highest vessel density and endothelial nitric oxide synthase (eNOS) expression. In NHP, PRP and MSCs result in similar vessel densities but incorporation of PRP ensues higher levels of eNOS expression. Overall, enrichment with PRP and MSCs yields extensive, mature vascularization of subcutaneous cell encapsulation devices. It is postulated that the individual properties of PRP and MSCs can be leveraged in a synergistic approach for maximal vascularization of cell encapsulation platforms.
- 25 May 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 306, 89-96
2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis
- 25 May 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 306, 89-96
2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis
- 2 May 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (9)
Endothelial senescence is induced by phosphorylation and nuclear export of telomeric repeat binding factor 2–interacting protein
The interplay among signaling events for endothelial cell (EC) senescence, apoptosis, and activation and how these pathological conditions promote atherosclerosis in the area exposed to disturbed flow (d-flow) in concert remain unclear. The aim of this study was to determine whether telomeric repeat-binding factor 2–interacting protein (TERF2IP), a member of the shelterin complex at the telomere, can regulate EC senescence, apoptosis, and activation simultaneously, and if so, by what molecular mechanisms. We found that d-flow induced p90RSK and TERF2IP interaction in a p90RSK kinase activity–dependent manner. An in vitro kinase assay revealed that p90RSK directly phosphorylated TERF2IP at the serine 205 (S205) residue, and d-flow increased TERF2IP S205 phosphorylation as well as EC senescence, apoptosis, and activation by activating p90RSK. TERF2IP phosphorylation was crucial for nuclear export of the TERF2IP-TRF2 complex, which led to EC activation by cytosolic TERF2IP-mediated NF-κB activation and also to senescence and apoptosis of ECs by depleting TRF2 from the nucleus. Lastly, using EC-specific TERF2IP-knockout (TERF2IP-KO) mice, we found that the depletion of TERF2IP inhibited d-flow–induced EC senescence, apoptosis, and activation, as well as atherosclerotic plaque formation. These findings demonstrate that TERF2IP is an important molecular switch that simultaneously accelerates EC senescence, apoptosis, and activation by S205 phosphorylation.
- 2 May 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (9)
Endothelial senescence is induced by phosphorylation and nuclear export of telomeric repeat binding factor 2–interacting protein
The interplay among signaling events for endothelial cell (EC) senescence, apoptosis, and activation and how these pathological conditions promote atherosclerosis in the area exposed to disturbed flow (d-flow) in concert remain unclear. The aim of this study was to determine whether telomeric repeat-binding factor 2–interacting protein (TERF2IP), a member of the shelterin complex at the telomere, can regulate EC senescence, apoptosis, and activation simultaneously, and if so, by what molecular mechanisms. We found that d-flow induced p90RSK and TERF2IP interaction in a p90RSK kinase activity–dependent manner. An in vitro kinase assay revealed that p90RSK directly phosphorylated TERF2IP at the serine 205 (S205) residue, and d-flow increased TERF2IP S205 phosphorylation as well as EC senescence, apoptosis, and activation by activating p90RSK. TERF2IP phosphorylation was crucial for nuclear export of the TERF2IP-TRF2 complex, which led to EC activation by cytosolic TERF2IP-mediated NF-κB activation and also to senescence and apoptosis of ECs by depleting TRF2 from the nucleus. Lastly, using EC-specific TERF2IP-knockout (TERF2IP-KO) mice, we found that the depletion of TERF2IP inhibited d-flow–induced EC senescence, apoptosis, and activation, as well as atherosclerotic plaque formation. These findings demonstrate that TERF2IP is an important molecular switch that simultaneously accelerates EC senescence, apoptosis, and activation by S205 phosphorylation.
- Open Access
- 28 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (7)
MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis
The possible association between the membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) and inflammation has been suggested, but the molecular mechanisms underlying this link, especially during atherogenesis, remain unclear. In endothelial cells (ECs) exposed to disturbed flow (d-flow), p90 ribosomal S6 kinase (p90RSK) bound to MAGI1, causing MAGI1-S741 phosphorylation and sentrin/SUMO-specific protease 2 T368 phosphorylation-mediated MAGI1-K931 deSUMOylation. MAGI1-S741 phosphorylation upregulated EC activation via activating Rap1. MAGI1-K931 deSUMOylation induced both nuclear translocation of p90RSK-MAGI1 and ATF-6-MAGI1 complexes, which accelerated EC activation and apoptosis, respectively. Microarray screening revealed key roles for MAGI1 in the endoplasmic reticulum (ER) stress response. In this context, MAGI1 associated with activating transcription factor 6 (ATF-6). MAGI1 expression was upregulated in ECs and macrophages found in atherosclerotic-prone regions of mouse aortas as well as in the colonic epithelia and ECs of patients with inflammatory bowel disease. Further, reduced MAGI1 expression in Magi1 –/+ mice inhibited d-flow–induced atherogenesis. In sum, EC activation and ER stress–mediated apoptosis are regulated in concert by two different types of MAGI1 posttranslational modifications, elucidating attractive drug targets for chronic inflammatory disease, particularly atherosclerosis.
- 28 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (7)
Open AccessMAGI1 as a link between endothelial activation and ER stress drives atherosclerosis
The possible association between the membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) and inflammation has been suggested, but the molecular mechanisms underlying this link, especially during atherogenesis, remain unclear. In endothelial cells (ECs) exposed to disturbed flow (d-flow), p90 ribosomal S6 kinase (p90RSK) bound to MAGI1, causing MAGI1-S741 phosphorylation and sentrin/SUMO-specific protease 2 T368 phosphorylation-mediated MAGI1-K931 deSUMOylation. MAGI1-S741 phosphorylation upregulated EC activation via activating Rap1. MAGI1-K931 deSUMOylation induced both nuclear translocation of p90RSK-MAGI1 and ATF-6-MAGI1 complexes, which accelerated EC activation and apoptosis, respectively. Microarray screening revealed key roles for MAGI1 in the endoplasmic reticulum (ER) stress response. In this context, MAGI1 associated with activating transcription factor 6 (ATF-6). MAGI1 expression was upregulated in ECs and macrophages found in atherosclerotic-prone regions of mouse aortas as well as in the colonic epithelia and ECs of patients with inflammatory bowel disease. Further, reduced MAGI1 expression in Magi1 –/+ mice inhibited d-flow–induced atherogenesis. In sum, EC activation and ER stress–mediated apoptosis are regulated in concert by two different types of MAGI1 posttranslational modifications, elucidating attractive drug targets for chronic inflammatory disease, particularly atherosclerosis.